Latest Breaking News On - Dekalb regional medical - Page 3 : comparemela.com
DeKalb Regional Medical Center is now offering two antibody therapies that may reduce COVID-19-related hospitalizations and emergency room visits in some patients treated within 10 days of symptom onset.
According to the U.S. Food and Drug Administration, the new Bamlanivimab and Regeneron monoclonal antibody therapy treatment is designed to minimize the severity of COVID-19 symptoms in patients with a mild or moderate case who do not require hospitalization.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system s ability to fight off harmful pathogens such as viruses. Unlike the vaccines that stimulate the immune system to produce antibodies, monoclonal antibodies are given to treat the early stages of COVID-19. The drug recently received emergency use authorization from the Food and Drug Administration. The U.S. Department of Health and Human Services has partnered with the Alabama Department of Public Health and other state agencies to distribute it.
AlabamaUnited-statesDekalb-regional-medical-centerAustin-croweAmiee-haygoodPharmacy-at-dekalb-regional-medical-centerUs-department-of-healthHuman-servicesDrug-administrationAlabama-department-of-public-healthAlabama-departmentPublic-health